冠動脈ステント留置術を受けた心房細動患者におけるリバーロキサバンとワルファリン併用療法の評価研究（REWRAPS）

基本情報

NCT ID

NCT02024230

ステータス

完了

試験のフェーズ

第4相

試験タイプ

介入

目標被験者数

500

治験依頼者名

Fujita Health University

概要

Antiplatelet therapy is indispensable for the prevention of stent thrombosis in patients who underwent coronary artery stenting. Similarly, anticoagulant therapy is essential for the prevention of cardiogenic embolism including cerebral infarction in AF patients. However, the combined antithrombotic therapy has been reported to increase the risk of major bleeding for AF patients after coronary stenting, New anticoagulant drugs that hardly interact with other drugs and do not need frequent blood tests have become commonly used. The purpose of this study is to assess the hypothesis that Rivaroxaban is non-inferior to Warfarin in the efficacy and safety for AF patients after coronary stenting

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)